Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2006

Mab for Pancreatic Cancer Receives Orphan Drug Designation

  • Morphotek® was granted orphan drug status for MORAb-009, a Mab against pancreatic cancer. MORAb-009 is an antibody that recognizes mesothelin, a cell surface glycoprotein over-expressed in a number of cancers.

    Researchers at the NCI and Johns Hopkins University independently validated the association of this protein in cancer and the therapeutic potential of drugs that can specifically target it, says Morphotek. Studies have demonstrated a high correlation of mesothelin expression with pancreatic, mesothelioma, ovarian, and non-small-cell-lung carcinomas, as well as several epithelial-based cancers.

    In December 2005, Morphotek signed an exclusive worldwide patent license agreement with the NCI giving it the right to develop and commercialize MORAb-009 and its molecular variants for the diagnosis and treatment of mesothelin-expressing tumors. There are six issued patents and two provisional patent applications that cover the antigen target and use of MORAb-009 antibodies for therapy.

    MORAb-009 will initially be developed for cancer. The first Phase I study is designed to evaluate MORAb-009 in subjects with pancreatic cancer mesothelioma and certain types of ovarian and lung cancers.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »